Bright Minds Biosciences is a clinical-stage biotech developing selective serotonergic drugs for central-nervous-system disorders. Its chemistry platform targets highly selective 5-HT2A and 5-HT2C receptor agonists designed to avoid 5-HT2B activity linked to safety concerns. Pipeline work centers on conditions such as drug-resistant epilepsy, depression and other neurological and psychiatric indications.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -3 | — |
| Q2 2025 | 0 | — | -5.2 | — |
| Q3 2025 | 0 | — | -4.1 | — |
| Q4 2025 | 0 | — | -7.6 | — |
| Q1 2026 | 0 | — | -10.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Shattuck Labs, Inc. (STTK), Paysign, Inc. (PAYS), Community West Bancshares (CWBC), Ironwood Pharmaceuticals, Inc. (IRWD), Helen of Troy Limited (HELE), Consensus Cloud Solutions, Inc. (CCSI)